Amphipathic DNA polymers exhibit antiviral activity against systemic Murine Cytomegalovirus infection

Virology Journal

Volumn 6, Issue , 2009, Pages

  Cardin, Rhonda D ^a   Bravo, Fernando J ^a   Sewell, Andrea P ^a   Cummins, James ^b   Flamand, Louis ^c   Juteau, Jean Marc ^d   Bernstein, David I ^a   Vaillant, Andrew ^d  

^a UNIVERSITY OF CINCINNATI   (United States)

^b SOUTHERN RESEARCH INSTITUTE   (United States)

^c Université Laval   (Canada)

^d NONE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; C10; DECANOATE SODIUM; DNA; EXCIPIENT; GANCICLOVIR; REP 9; REP 9C; UNCLASSIFIED DRUG; POLYCYTIDYLIC ACID; POLYNUCLEOTIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; CPG ISLAND; CYTOMEGALOVIRUS INFECTION; DRUG EFFICACY; DRUG POTENCY; DRUG TOLERABILITY; FEMALE; GUINEA PIG; HUMAN; IC 50; IN VITRO STUDY; IN VIVO STUDY; LIVER; MOUSE; NONHUMAN; SPLENOMEGALY; TREATMENT OUTCOME; VIRUS INHIBITION; VIRUS PLAQUE; VIRUS REPLICATION; VIRUS TITRATION; ANIMAL; BAGG ALBINO MOUSE; CELL CULTURE; CHEMISTRY; DRUG EFFECT; MUROMEGALOVIRUS; ORAL DRUG ADMINISTRATION;

ANIMALIA; CAVIA; CYTOMEGALOVIRUS; HUMAN HERPESVIRUS 1; HUMAN HERPESVIRUS 2; HUMAN HERPESVIRUS 3; HUMAN HERPESVIRUS 4; HUMAN HERPESVIRUS 6; MAIZE CHLOROTIC MOTTLE VIRUS; MURID HERPESVIRUS 1; MURINAE; MUS;

ADMINISTRATION, ORAL; ANIMALS; ANTIVIRAL AGENTS; CELLS, CULTURED; CYTOMEGALOVIRUS INFECTIONS; DNA; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; MUROMEGALOVIRUS; POLY C; POLYNUCLEOTIDES;

EID: 74949085441     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-6-214     Document Type: Article

References (52)

1. Cytomegalovirus infection. RF Pass, Pediatr Rev 2002 23 163 170 10.1542/pir.23-5-163 11986492
2. Antiviral drugs for cytomegalovirus diseases. KK Biron, Antiviral Res 2006 71 154 163 10.1016/j.antiviral.2006.05.002 16765457
3. Clinical impact of ganciclovir-resistant cytomegalovirus infections in solid organ transplant patients. G Boivin N Goyette C Gilbert A Humar E Covington, Transpl Infect Dis 2005 7 166 170 10.1111/j.1399-3062.2005.00112.x 16390409
4. Human cytomegalovirus resistance to antiviral drugs. C Gilbert G Boivin, Antimicrob Agents Chemother 2005 49 873 883 10.1128/AAC.49.3.873-883.2005 15728878
5. Phosphorothioate oligonucleotides inhibit human immunodeficiency virus type 1 fusion by blocking gp41 core formation. A Vaillant JM Juteau H Lu S Liu C Lackman-Smith R Ptak S Jiang, Antimicrob Agents Chemother 2006 50 1393 1401 10.1128/AAC.50.4.1393-1401.2006 16569857
6. Amphipathic DNA polymers are candidate vaginal microbicides and block herpes simplex virus binding, entry and viral gene expression. EM Guzman N Cheshenko V Shende MJ Keller N Goyette JM Juteau G Boivin A Vaillant BC Herold, Antivir Ther 2007 12 1147 1156 18240855
7. Inhibition of cellular entry of lymphocytic choriomeningitis virus by amphipathic DNA polymers. AM Lee JM Rojek A Gundersen U Stroher JM Juteau A Vaillant S Kunz, Virology 2008 372 107 117 10.1016/j.virol.2007.10.016 18022208
8. Amphipathic DNA polymers inhibit hepatitis C virus infection by blocking viral entry. T Matsumura Z Hu T Kato M Dreux YY Zhang M Imamura N Hiraga JM Juteau FL Cosset K Chayama, et al. Gastroenterology 2009 137 673 681 10.1053/j.gastro.2009.04.048 19394333
9. Atomic structure of the ectodomain from HIV-1 gp41. W Weissenhorn A Dessen SC Harrison JJ Skehel DC Wiley, Nature 1997 387 426 430 10.1038/387426a0 9163431
10. The ectodomain of herpes simplex virus glycoprotein H contains a membrane alpha-helix with attributes of an internal fusion peptide, positionally conserved in the herpesviridae family. T Gianni PL Martelli R Casadio G Campadelli-Fiume, J Virol 2005 79 2931 2940 10.1128/JVI.79.5.2931-2940.2005 15709012
11. Crystal structure of glycoprotein B from herpes simplex virus 1. EE Heldwein H Lou FC Bender GH Cohen RJ Eisenberg SC Harrison, Science 2006 313 217 220 10.1126/science.1126548 16840698
12. Identification of an N-terminal trimeric coiled-coil core within arenavirus glycoprotein 2 permits assignment to class I viral fusion proteins. B Eschli K Quirin A Wepf J Weber R Zinkernagel H Hengartner, J Virol 2006 80 5897 5907 10.1128/JVI.00008-06 16731928
13. Structure of the haemagglutinin membrane glycoprotein of influenza virus at 3 A resolution. IA Wilson JJ Skehel DC Wiley, Nature 1981 289 366 373 10.1038/289366a0 7464906
14. Structural characterization of the human respiratory syncytial virus fusion protein core. X Zhao M Singh VN Malashkevich PS Kim, Proc Natl Acad Sci USA 2000 97 14172 14177 10.1073/pnas.260499197 11106388
15. Virus entry: molecular mechanisms and biomedical applications. DS Dimitrov, Nat Rev Microbiol 2004 2 109 122 10.1038/nrmicro817 15043007
16. Fomivirsen-a phosphorothioate oligonucleotide for the treatment of CMV retinitis. MD de Smet CJ Meenken GJ van den Horn, Ocul Immunol Inflamm 1999 7 189 198 10.1076/ocii.7.3.189.4007 10611727
17. Amphipathic DNA polymers exhibit antiherpetic activity in vitro and in vivo. DI Bernstein N Goyette R Cardin ER Kern G Boivin J Ireland JM Juteau A Vaillant, Antimicrob Agents Chemother 2008 52 2727 2733 10.1128/AAC.00279-08 18505857
18. Induction of systemic TH1-like innate immunity in normal volunteers following subcutaneous but not intravenous administration of CPG a synthetic B-class CpG oligodeoxynucleotide TLR9 agonist. AM Krieg SM Efler M Wittpoth MJ Al Adhami HL Davis, J Immunother 7909 27 460 471 10.1097/00002371-200411000- 00006
19. Mucosal and parenteral vaccination against acute and latent murine cytomegalovirus (MCMV) infection by using an attenuated MCMV mutant. MR MacDonald XY Li RM Stenberg AE Campbell HWt Virgin, J Virol 1998 72 442 451 9420244
20. Progressive loss of CD8+ T cell-mediated control of a gamma-herpesvirus in the absence of CD4+ T cells. RD Cardin JW Brooks SR Sarawar PC Doherty, J Exp Med 1996 184 863 871 10.1084/jem.184.3.863 9064346
21. The M33 chemokine receptor homolog of murine cytomegalovirus exhibits a differential tissue-specific role during in vivo replication and latency. RD Cardin GC Schaefer JR Allen NJ Davis-Poynter HE Farrell, J Virol 2009 83 7590 7601 10.1128/JVI.00386-09 19439478
22. Effect of maternal treatment with cyclic HPMPC in the guinea pig model of congenital cytomegalovirus infection. FJ Bravo RD Cardin DI Bernstein, J Infect Dis 2006 193 591 597 10.1086/499603 16425139
23. Comparison between human cytomegalovirus pUL97 and murine cytomegalovirus (MCMV) pM97 expressed by MCMV and vaccinia virus: pM97 does not confer ganciclovir sensitivity. M Wagner D Michel P Schaarschmidt B Vaida S Jonjic M Messerle T Mertens U Koszinowski, J Virol 2000 74 10729 10736 10.1128/JVI.74.22.10729-10736.2000 11044117
24. Detection of murine cytomegalovirus DNA in circulating leukocytes harvested during acute infection of mice. JF Bale Jr ME O'Neil, J Virol 1989 63 2667 2673 2542580
25. Reactivation of murine cytomegalovirus from latency. RD Cardin JM Boname GB Abenes SA Jennings ES Mocarski, Multidisciplinary Approaches to Understanding Cytomegalovirus Disease Amsterdam: Elsevier, Plotkin SA, Michelson S, 1993 101 110
26. Biphasic viremia and viral gene expression in leukocytes during acute cytomegalovirus infection of mice. TM Collins MR Quirk MC Jordan, J Virol 1994 68 6305 6311 8083970
27. The murine cytomegalovirus as a model for the study of viral pathogenesis and persistent infections. JB Hudson, Arch Virol 1979 62 1 29 10.1007/BF01314900 231945
28. Peripheral blood mononuclear phagocytes mediate dissemination of murine cytomegalovirus. CA Stoddart RD Cardin JM Boname WC Manning GB Abenes ES Mocarski, J Virol 1994 68 6243 6253 8083964
29. Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice. S Agrawal J Temsamani JY Tang, Proc Natl Acad Sci USA 1991 88 7595 7599 10.1073/pnas.88.17.7595 1881900
30. Pharmacokinetics, tissue distribution, and stability of antisense oligodeoxynucleotide phosphorothioate ISIS 3466 in mice. Y Saijo L Perlaky H Wang H Busch, Oncol Res 1994 6 243 249 7865900
31. Antisense oligonucleotide inhibitors for the treatment of cancer: 1. Pharmacokinetic properties of phosphorothioate oligodeoxynucleotides. RS Geary JM Leeds SP Henry DK Monteith AA Levin, Anticancer Drug Des 1997 12 383 393 9236854
32. Pharmacokinetics, metabolism, and elimination of a 20-mer phosphorothioate oligodeoxynucleotide (CGP 69846A) after intravenous and subcutaneous administration. JA Phillips SJ Craig D Bayley RA Christian R Geary PL Nicklin, Biochem Pharmacol 1997 54 657 668 10.1016/S0006-2952(97)00190-1 9310342
33. Comparison of pharmacokinetics and tissue disposition of an antisense phosphorothioate oligonucleotide targeting human Ha-ras mRNA in mouse and monkey. RZ Yu RS Geary JM Leeds T Watanabe M Moore J Fitchett J Matson T Burckin MV Templin AA Levin, J Pharm Sci 2001 90 182 193 10.1002/1520-6017(200102)90: 2<182:AID-JPS9>3.0.CO;2-F 11169535
34. Cross-species pharmacokinetic comparison from mouse to man of a second-generation antisense oligonucleotide, ISIS 30 targeting human apolipoprotein B-100. RZ Yu TW Kim A Hong TA Watanabe HJ Gaus RS Geary, Drug Metab Dispos 1012 35 460 468 10.1124/dmd.106.012401
35. Tetradecylmaltoside (TDM) enhances in vitro and in vivo intestinal absorption of enoxaparin, a low molecular weight heparin. T Yang JJ Arnold F Ahsan, J Drug Target 2005 13 29 38 10.1080/10611860400020191 15848952
36. Intravail: highly effective intranasal delivery of peptide and protein drugs. ET Maggio, Expert Opin Drug Deliv 2006 3 529 539 10.1517/17425247.3.4.529 16822227
37. Oral bioavailability and multiple dose tolerability of an antisense oligonucleotide tablet formulated with sodium caprate. AA Raoof P Chiu Z Ramtoola IK Cumming C Teng SP Weinbach GE Hardee AA Levin RS Geary, J Pharm Sci 2004 93 1431 1439 10.1002/jps.20051 15124202
38. Oral delivery of antisense oligonucleotides in man. LG Tillman RS Geary GE Hardee, J Pharm Sci 2008 97 225 236 10.1002/jps.21084 17721945
39. An apolipoprotein B antisense oligonucleotide lowers LDL cholesterol in hyperlipidemic mice without causing hepatic steatosis. RM Crooke MJ Graham KM Lemonidis CP Whipple S Koo RJ Perera, J Lipid Res 2005 46 872 884 10.1194/jlr.M400492-JLR200 15716585
40. Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B. JJ Kastelein MK Wedel BF Baker J Su JD Bradley RZ Yu E Chuang MJ Graham RM Crooke, Circulation 2006 114 1729 1735 10.1161/CIRCULATIONAHA.105. 606442 17030687
41. A heptad repeat in herpes simplex virus 1 gH, located downstream of the alpha-helix with attributes of a fusion peptide, is critical for virus entry and fusion. T Gianni L Menotti G Campadelli-Fiume, J Virol 2005 79 7042 7049 10.1128/JVI.79.11.7042-7049.2005 15890943
42. Effective postexposure treatment of retrovirus-induced disease with immunostimulatory DNA containing CpG motifs. AR Olbrich S Schimmer K Heeg K Schepers TN Schumacher U Dittmer, J Virol 2002 76 11397 11404 10.1128/JVI.76.22.11397-11404.2002 12388700
43. An immunostimulatory oligodeoxynucleotide containing a cytidine-guanosine motif protects senescence-accelerated mice from lethal influenza virus by augmenting the T helper type 1 response. L Dong I Mori MJ Hossain B Liu Y Kimura, J Gen Virol 2003 84 1623 1628 10.1099/vir.0.19029-0 12771433
44. A protective role of locally administered immunostimulatory CpG oligodeoxynucleotide in a mouse model of genital herpes infection. AM Harandi K Eriksson J Holmgren, J Virol 2003 77 953 962 10.1128/JVI.77.2.953-962.2003 12502811
45. Human cytomegalovirus activates inflammatory cytokine responses via CD14 and Toll-like receptor 2. T Compton EA Kurt-Jones KW Boehme J Belko E Latz DT Golenbock RW Finberg, J Virol 2003 77 4588 4596 10.1128/JVI.77.8.4588-4596.2003 12663765
46. TLR9-dependent recognition of MCMV by IPC and DC generates coordinated cytokine responses that activate antiviral NK cell function. A Krug AR French W Barchet JA Fischer A Dzionek JT Pingel MM Orihuela S Akira WM Yokoyama M Colonna, Immunity 2004 21 107 119 10.1016/j.immuni.2004.06.007 15345224
47. Toll-like receptors 9 and 3 as essential components of innate immune defense against mouse cytomegalovirus infection. K Tabeta P Georgel E Janssen X Du K Hoebe K Crozat S Mudd L Shamel S Sovath J Goode, et al. Proc Natl Acad Sci USA 2004 101 3516 3521 10.1073/pnas.0400525101 14993594
48. Role for TLR2 in NK cell-mediated control of murine cytomegalovirus in vivo. E Szomolanyi-Tsuda X Liang RM Welsh EA Kurt-Jones RW Finberg, J Virol 2006 80 4286 4291 10.1128/JVI.80.9.4286-4291.2006 16611887
49. IL-1B Attenuates IFN-aB-induced antiviral activity and STAT1 activation in the liver: involvement of proteasome-dependent pathway. P Tian X Shen H Feng B Gao, J Immunol 2000 165 3959 3965 11034404
50. Effects of tumor necrosis factor-alpha treatment on mortality in murine cytomegalovirus-infected mice. KP Anderson YS Lie MA Low EH Fennie, Antiviral Res 1993 21 343 355 10.1016/0166-3542(93)90012-8 8215304
51. Spectroscopic evidence for the formation of four-stranded solution structure of oligodeoxycytidine phosphorothioate. H Kanehara M Mizuguchi K Tajima K Kanaori K Makino, Biochemistry 1997 36 1790 1797 10.1021/bi961528c 9048563
52. Pivotal role of animal models in the development of new therapies for cytomegalovirus infections. ER Kern, Antiviral Res 2006 71 164 171 10.1016/j.antiviral.2006.05.018 16828175